School of Pharmacy and Pharmaceutical Sciences & Molecular Therapeutics for Cancer Ireland, Trinity College Dublin, Dublin 2, Ireland.
Breast Cancer Res Treat. 2010 Oct;123(3):613-25. doi: 10.1007/s10549-010-0980-2. Epub 2010 Jun 15.
Early detection of cancer is vital to improved overall survival rates. At present, evidence is accumulating for the clinical value of detecting occult tumor cells in peripheral blood, plasma, and serum specimens from cancer patients. Both molecular and cellular approaches, which differ in sensitivity and specificity, have been used for such means. Circulating tumor cells and extracellular nucleic acids have been detected within blood, plasma, and sera of cancer patients. As the presence of malignant tumors are clinically determined and/or confirmed upon biopsy procurement-which in itself may have detrimental effects in terms of stimulating cancer progression/metastases-minimally invasive methods would be highly advantageous to the diagnosis and prognosis of breast cancer and the subsequent tailoring of targeted treatments for individuals, if reliable panels of biomarkers suitable for such an approach exist. Herein, we review the current advances made in the detection of such circulating tumor cells and nucleic acids, with particular emphasis on extracellular nucleic acids, specifically extracellular mRNAs and discuss their clinical relevance.
早期发现癌症对于提高整体存活率至关重要。目前,越来越多的证据表明,在癌症患者的外周血、血浆和血清样本中检测隐匿性肿瘤细胞具有临床价值。这些方法的检测使用了分子和细胞方法,其在灵敏度和特异性上有所不同。已经在癌症患者的血液、血浆和血清中检测到循环肿瘤细胞和细胞外核酸。由于恶性肿瘤的存在是通过临床诊断和/或活检获得确定的,而活检本身可能会对癌症的进展/转移产生不利影响,因此,如果存在适用于这种方法的可靠生物标志物组合,那么微创方法将非常有利于乳腺癌的诊断和预后,以及随后为个体定制靶向治疗。在此,我们综述了目前在检测这些循环肿瘤细胞和核酸方面的进展,特别强调了细胞外核酸,具体是细胞外 mRNA,并讨论了它们的临床相关性。